Publications for the last 7 years
Presentations made at international conferences in the last 7 years
Papers presented at national scientific meetings
LIST OF PUBLICATIONS FOR THE LAST 7 YEARS
Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel. Anti-Cancer Drugs In Press. Locke VL., Davey RA. and Davey MW. (2003)
The use of Tris-Lipidation to modify drug interactions with P-glycoprotein and MRP1. Br. J. Pharmacol. 137:1280-1286. Davey RA., Davey MW., Cullen KV., Wells XE., Francis CL., Williams H-M., Yang Q., Moghaddam MJ., Widmer F. and Whittaker RG. (2002)
Fractionated irradiation of H69 small cell lung cancer cells causes stable radiation and drug resistance with increased MRP1, MRP2 and topoisomerase IIa expression. Int. J. Rad. Oncol. Biol. Phys. 54:895-902 Henness S., Davey MW., Harvie RM., and Davey RA. (2002)
Activity of drugs from Traditional Chinese Medicine towards sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Diseases 28:160-168 Efferth T., Davey M., Olbrich A., Rücker G., Gebhart E. and Davey R. (2002)
Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews. (1):CD003474. Pavlakis N. and Stockler M. (2002)
Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock. J. Clin. Oncol. 20:1446-1448. Marx GM., Steer CB., Harper P., Pavlakis N., Rixe O., Khayat D. (2002)
Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neuro Oncol. 54:31-38. Marx GM., Pavlakis N., McCowatt., Boyle FM., Levi JL., Bell Dr., Cook R., Biggs M., Little N. and Wheeler HR. (2001)
The experimental neuroprotectant Leukaemia Inhibitory Factor (LIF) does not compromise antitumor activity of paclitaxel, cisplatin and carboplatin. Cancer Chemother. Pharmacol. 48:429-434. Boyle FM., Beatson C., Monk R. Grant SL. and Kurek JB. (2001)
Verapamil-stimulated glutathione transport by the multidrug resistasnce-associated protein (MRP1) in leukaemia cells. Biochem Pharmacol. 62:417-424. Cullen KV., Davey RA. and Davey MW. (2001)
Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001 15:675-681. Jones K., Hoggard PG., Sales SD., Khoo S., Davey R. and Back DJ. (2001)
Drug resistance proteins MRP and P-glycoprotein do not confer resistance to Fas-induced cell death. Cytometry 43:189-194. Cullen K., Davey R. and Davey M. (2001)
Paclitaxel sensitisation of multidrug resistant cells to chemotherapy is independent of cell cycle. Cytometry 43:170-174 Locke V., Davey R. and Davey M. (2001)
Drug resistance does not correlate with resistance to Fas-mediated apoptosis. Leukemia Res. 25:69-75 Cullen KV., Davey RA. and Davey MW. (2001)
The Predictive Value of Body Protein in Chemotherapy Induced Toxicity. Cancer 88:796-803. Aslani A., Smith RC., Allen BJ., Pavlakis N. and Levi JA. (2000)
Changes in body composition during breast cancer chemotherapy with the CMF regimen. Breast Cancer Res. & Treat. 57:285-290. Aslani A., Smith RC., Allen BJ., Pavlakis N. and Levi JA. (1999)
Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells. Br. J. Haematol. 106:86-91 Locke V., Davey R. And Davey M. (1999)
Pain management. In Oncologic Therapies, ed. Volks E., and Golomb HM., Springer, pp 1099-1114. Boyle FM. and Grossman SA. (1998)
Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neuro-Oncol. 41:107-116. Boyle FM., Wheeler HR. and Shenfield GM. (1998)
The extended-MDR phenotype. Cytotechnology 27:237-247 Davey RA. and Davey MW. (1998)
ARA a novel ABC transporter, is located at 16p13.1 is deleted in the inv(16) leukaemias and is shown to be expressed in primative haematopoietic precursors. Genomics 51:455-458 Kuss BJ., O’Neill GM., Eyre H., Doggett NA., Callen DF. and Davey RA. (1998)
Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int. J. Cancer 76:702-708 Su GMI., Davey MW. and Davey RA. (1998)
Amplification and expression of the ABC-transporters, ARA and MRP in a series of multidrug resistant leukaemia cell sublines. Brit. J. Cancer 77:2076-2080 O’Neill GM., Peters G., Harvie RM.,MacKenzie HB., Henness S. and Davey RA. (1998)
The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells. Biochem. Pharmacol. 55:1283-1289. Grech KV., Davey RA. and Davey MW. (1998)
Fatal pulmonary toxicity following gemcitabine. Cancer 80:286-291. Pavlakis N., Bell DR., Millward M. and Levi JA. (1997)
Adverse interaction of herbal medicine with breast cancer treatment. Med. J. Aust. 167:286. Boyle, FM. (1997)
Increased MRP expression is associated with resistance to radiation, anthracyclines and etoposide induced in cells treated with fractionated g -radiation. Int. J. Cancer 73:161-167. Harvie RM., Davey MW. and Davey RA. (1997)
Potential of Circumvention of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA), idarubicin and paclitaxel to circumvent three multidrug resistance phenotypes in vitro. Cancer Chemother. Pharmacol. 39:424-430. Davey R., Su G., Hargraves R., Harvie R., Baguley B. and Davey M. (1997)
Glutamate ameliorates experimental vincristine neuropathy. J. Pharmacol. Exp. Therap. 279:410-415. Boyle FM., Wheeler HR. and Shenfield GM. (1996)
Deliberate overdose of uranium: Toxicity and treatment. Nephron 72: 313-317. Pavlakis N., Pollock CA., McLean G. and Bartrop R. (1996)
Extended-multidrug resistance in haematopoetic cells. Br. J. Haematology 95:587-595. Marks DC., Su GMI., Davey RA and Davey MW. (1996)
The Anthracycline Resistance Associated (ara) gene, a novel gene associated with multidrug resistance in a human leukemia cell line. Br J Cancer 74:1331-1335. Longhurst TJ., O'Neill GM., Harvie RM. and Davey RA. (1996)
Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells. Leukemia Research, 20:657-664. Davey MW., Hargrave RM. and Davey RA. (1996)
Paclitaxel sensitised multidrug resistant cells to radiation. Anti-cancer Drugs, 7:182-8 Mote PA., Davey MW., Davey RA. and Oliver L. (1996)
Extended multidrug resistance in leukaemia cell lines. Cytotechnology, 19:271. Marks D., Su G., Davey M. and Davey R. (1995)
Expression of multidrug resistance in response to differentiation in the K562 human leukaemia cell line. Biochem Pharmacol., 50:475-80. Marks DC., Davey MW., Davey RA and Kidman AD. (1995)
Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anti-cancer Drugs, 6:432-7. Hargrave RM., Davey MW., Davey RA. and Kidman AD. (1995)
Drug resistance mechanisms and mrp expression in response to epirubicin treatment in a human leukaemia cell line. Leukemia Res., 19:275-82. Davey RA., Longhurst TJ., Davey MW., Belov L., Harvie RM., Hancox D. and Wheeler H. (1995)
LIST OF PRESENTATIONS MADE AT INTERNATIONAL CONFERENCES IN THE LAST 7 YEARS
Changes in gene expression and response to radiation in a radiation and drug resistant small cell lung cancer cell line. Proc. Am. Assoc. Cancer Res./Nature Genetics, Oncogenomics Meeting. Henness S., Davey M., Harvie R., Wasinger V., Corthals G., Banyer J. and Davey R. (2002)
PI-88 demonstrates consistent positive interaction in combination with cisplatin, paclitaxel, vinorelbine, doxorubicin, 5-FU and gemcitabine in the BC1 syngeneic rat adenocarcinoma model. Proc. Am. Assoc. Cancer Res. 43:2605. Pavlakis N., Monk R., Parish C., Freeman C., Podger D., Davey R. and Wheeler H. (2002)
Development of a rat glioma model for testing chemotherapy-thalidomide interactions. Proc. Am. Assoc. Cancer Res. 43:2591. Murphy-Poulton S., ? Gu S., Mather L., Monk R., Boyle F., Wheeler H. (2002)
Response to radiation in the H69 human SCLC cell line involves changes in topoisomerase IIa and MRP2 expression. Proc. Am. Assoc. Cancer Res. 43:2088. Henness S., Harvie RM., Davey MW. and Davey RA. (2002)
PI-88, a novel heparanase inhibitor and anti-angiogenic agent, interacts positively with cisplatin, paxitaxel, doxorubicin and gemcytabine in a syngeneic rat adenocarcinoma model. AACR Molecular Targets and Cancer Therapeutics. Pavlakis N., Monk R., Parish C., Freeman C., Podger D., Davey R., Wheeler H. (2001)
The role of insulin-like growth factor binding protein-2 (IGFBP-2) in ovarian cancer. Proc. Am. Assoc. Cancer Res. 42:4109 Baron-Hay SE., Boyle FM., Ferrier A. and Scott C. (2001)
Multidrug resistance (MDR) and radiation resistance in human small cell lung cancer cells treated with fractionated radiation. Proc. Am. Assoc. Cancer Res. 41:4507 Harvie RM., Sun HP., Henness S., Peters GB., Davey MW. and Davey RA. (2000)
The heparanase inhibitor PI-88 reduces tumor growth in two rat mammary adenocarcinoma models, demonstrating schedule dependency and possible synergy with cisplatin (cis). Proc. Am. Assoc. Cancer Res. 41:1953 Pavlakis N., Parish C., Freeman C., Davey R., Levi JA. and Wheeler H. (2000)
Phase II Study of Thalidomide as an Anti-Angiogenic Agent in the Treatment of Recurrent Glioblastoma Multiforme (GBM). Proc. Am. Soc. Clin. Oncol. 36:613. Marx GG., McCowatt S., Boyle F., Pavlakis P., Levi JA., Bell DR., Freilich R., Cook R., BiggsM., Little N. and Wheeler HR. (2000)
Inhaled Fentanyl via the AERx system for the treatment of breakthrough cancer pain. Proc. Am. Pain Soc. Boyle F., Mather L., Lam J., Morishige R., Otulana B., Dayton F., Rubsamen R. and Thipphawong JB. (2000)
Modulation of multidrug resistance-associated protein (MRP)-mediated multidrug resistance (MDR) cause an MRP-dependent decrease in cellular glutathione. Proc. Am. Assoc. Cancer Res. 41:4281. Cullen K., Davey R. and Davey M. (2000)
Reversal of drug resistance in small cell lung cancer cells by taxol. Proc. Am. Assoc. Cancer Res. 41:1708. Locke V., Davey R. and Davey M. (2000)
Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme. Proc. Am. Soc. Clin. Oncol. 36:101 Marx G., McCowatt S., Boyle FM. et al (2000)
The experimental neuroprotectant leukemia inhibition factor (LIF) does not inhibit cytotoxicity of paclitaxel and cisplatin. Proc. Am. Assoc. Cancer Res. 41:4474 Boyle FM., Monk R., Beatson C. and Kurek J. (2000)
Characterisation of resistance to radiation and chemotherapeutic drugs in small cell lung cancer cells. Australia & New Zealand Society of Occupational Medicine Hobart Annual Meeting, Invited presentation. Davey R and Davey M. (2000)
Does the 3’ untranslated region of the ABC transporter MRP regulate its expression? Proc. Am. Assoc. Cancer Res. 41:1154 Henness S., O’Neill GM. and Davey RA. (2000)
The emperor’s new clothes: vincristine distribution in experimental glioma. Proc. Soc. Neuro-Oncol. Boyle FM., Eller S. and Grossman SC. (1999)
Prevention of experimental vinorelbine neuropathy with glutamate. Proc. Am. Assoc. Cancer Res. 40:2564. Boyle FM., Monk RM., Wheeler HR. (1999)
Paclitaxel sensitisation of multidrug resistant cells to chemotherapy is independent of cell cycle. Proc. Int. Soc. Flow Cytometry SA Latt Conf:28. Locke V., Davey R. and Davey M. (1999)
Multidrug resistance (MDR) is not associated with resistance to Fas-mediated apoptosis. Proc. Int. Soc. Flow Cytometry. SA Latt Conf:27. Cullen K., Davey R. and Davey M. (1999)
Application of walking track analysis to the study of cytoxic neuropathy. Proc. Am. Assoc. Cancer Res. 39:4079 Boyle F.M., Monk R.E., Gidding C. and Wheeler H.R. (1998)
The influence of insulin-like growth factor I (IGF-I) on vincristine induced neuropathy, rhabdomyosarcoma growth, and the antitumor effect of vincristine (vcr) in animal models. Proc. Am. Assoc. Cancer Res. 39:4052. Gidding CEM., Boyle F., Monk R., de Graaf SSN., Camps WA., Cheshire P. and Houghton PJ. (1998)
The anthracycline resistance associated gene: a ubiquitous ATP-dependent transporter. Proc. Am. Assoc. Cancer Res. 39:1161 O’Neill GM., Henness S. and Davey RA. (1998)
Role of glutathione in multidrug resistance (MDR) mediated by the multidrug resistance-associated protein (MRP). Proc. Am. Assoc. Cancer Res. 39:1157 Grech KV., Davey MW. and Davey RA. (1998)
The potential of paclitaxel as a response modifier in Small Cell Lung Cancer cells with extended-multidrug resistance. Proc. Am. Assoc. Cancer Res. 39:1167 Davey RA., Su GM. and Davey MW. (1998)
g -Radiation causes increased MRP expression in vitro. Proc. Am. Assoc. Cancer Res. 38:1693. Davey R.A., Harvie R.M. and Davey M.W. (1997)
Drug transport in MDR leukaemia cells. FEBS ABC Transporter Meeting, AUSTRIA: P3-5. Davey M., Grech K. and Davey R. (1997)
Expression of ara (a novel ABC transporter), and MRP in a series of drug resistant sublines. FEBS ABC Transporter Meeting, AUSTRIA: ST-3. Davey R., Harvie R., O’Neill G. and Davey M. (1997)
The experimental neuroprotectant glutamate does not inhibit cytotoxicity of vinca alkaloids, cisplatin or paclitaxel. Proc. Am. Assoc. Cancer Res. 38:4077. Boyle F., Monk R., Wheeler H., Shenfield G. (1997)
A novel gene (ara) associated with drug resistance. Proc. Am. Assoc. Cancer Res., 37:2191. O'Neill GM., Longhurst T., Harvie RM., and Davey RA. (1996)
Prevention of experimental paclitaxel neuropathy with glutamate. Proc. Am. Assoc. Cancer Res., 37:1974. Boyle F., Monk R., Davey R., Wheeler H. and Shenfield G. (1996)
Induction of extended multidrug resistance in the H82 human SCLC cell in response to drug treatment. Proc. Am. Assoc. Cancer Res. Inducible Genomic Responses, B:16. Su GM., Davey MW. and Davey RA. (1996)
Development and characterisation of drug-resistant H82 small cell lung cancer cell lines. Proc. Am. Assoc. Cancer Res. 36:2025. Su GM., Davey MW. and Davey RA. (1995)
Paclitaxel sensitises multidrug resistant cells to radiation. Engineering and Physics in Medicine, Queenstown, NZ. Mote P., Davey MW., Davey RA. and Oliver L. (1995)
Extended multidrug resistance in leukaemia cell lines. European Tissue Culture Society's International Meeting on Drug Resistance in Cancer, Dublin, Ireland. Marks D., Su G., Davey M. and Davey R. (1995)
Drug transport associated with MRP-expressing and P-glycoprotein-expressing human leukaemia sublines. FAOBMB's Comparative aspects of translocating ATPases, Leura, Australia. Davey M., Davey R., Harvie R., Hargrave R. and Barnetson A. (1995)
Amelioration of vincristine neuropathy with glutamate. The Cytoskeleton and Cancer, Marsville,? Boyle F., Monk R., Davey R., Wheeler H. and Shenfield G. (1995)
Amelioration of cisplatin neuropathy by glutamate. Supportive are in Cancer 3: 370. Boyle F., Monk R., Wheeler H. and Shenfield G. (1995)
PAPERS PRESENTED AT NATIONAL SCIENTIFIC MEETINGS
Thalidomide alone and in combination with cisplati/gemcitabine chemotherapy for malignant mesothelioma (MM): Preliminary results from two phase II studies. Frontiers of Research in Occupational Respiratory Health Meeting, Dust Diseases Board. Wheeler H. & Pavlakis N. (2002)
Characterisation of resistance to radiotherapy and chemotherapeutic drugs in lung cancer cells. Frontiers of Research in Occupational Respiratory Health Meeting, Dust Diseases Board. Davey R., (2002)
PI-88, a novel heparanase inhibitor and anti-angiogenic agent, demonstrates potential synergy with several cytotoxic drugs and thalidomide in a syngeneic rat adenocarcinoma model. Proc, Med. Oncol. Group Aust. Pavlakis N., Monk R., Parish C., Freeman C., Podger D., Davey R., Wheeler H. (2001)
Identification of the origins of the amplifications in drug resistant leukaemia cells by chromosomal microdissection. Proc. Aust. Soc. Med. Res. O025. Mahjoubi F., Hill R., O’Neill G., DaveyR., Peters G. (2001)
Quality of life (QOL) evaluation of patients with malignant mesothelioma (MM) receiving thalidomide with/without chemotherapy. Proc. Clin. Oncol. Soc. Australia. Williams G., Harvie R., Wheeler H. and Pavlakis N. (2001)
Multiple mechanisms associated with low-level drug resistance in U937 human leukaemia cells. Proc. Aust. Soc. Med. Res. P131. Stordal B., Davey R. and Davey M. (2001)
The molecular changes involved in a cellular model of radiation and drug resistance in small cell lung cancer. Proc. Aust. Soc. Med. Res. P123. Henness S., Harvie R., Wasinger V., Corthals G., Davey M. and Davey R. (2001)
Burnout in Autralian Cancer Professionals Proc. Clin. Oncol. Soc. Australia. Jusuf S., Boyle F. and Dunn S. (2000)
Barriers to optimal cancer pain management: Knowledge and attitutes of junior medical officers. Proc. Clin. Oncol. Soc. Australia. Brown R., Bandler L., Heinrich P., Dunn S. and Boyle F. (2000)
Imroproving communication networks: A National program for rural health professionals involved in the management of women receiving chemotherapy for early breast cancer. Proc. Clin. Oncol. Soc. Australia. Dalton L., Luxford K., McInnes L., Goldstein D., Underhill C., Gill K., Freeman V., Zorbas H., Lawrence R. and Boyle F. (2000)
The role of IGF BP-2 in ovarian cancer. Proc. Clin. Oncol. Soc. Australia. Baron-Hay S., Boyle F., Ferrier A. and Scott C. (2000)
When the news is bad: optimising the learning environment. Proc. Clin. Oncol. Soc. Australia. Heinrich P., Boyle F., Garlan K. and Dunn S. (2000)
Keeping abreast of shared data audit: do the eyes have it. MOGA. Hennessy MP. and Boyle FM. (2000)
The role of the insulin-like growth factor system in ovarian cancer. MOGA. Baron-Hay S., Boyle F. and Scott C. (2000)
What you don't know can hurt you: Barriers to cancer pain management. Proc. Clin. Oncol. Soc. Aust. A80. Potter V., Wiseman E., Dunn S. and Boyle F. (1999)
Inhibition of adenocarcinoma growth in rats by the heparanase inhibitor PI-88. Proc. Aust. Soc. Med. Res. 38:P2-5 Pavlakis N., Parish C., Freeman C., Davey R. and Wheeler H. (1999)
Thalidomide as palliative treatment of advanced malignant mesothelioma. Proc. Clin. Oncol. Soc. Aust. A116. Pavlakis N., Marx G., McCowatt S., Bell D., Boyle F., Levi J. and Wheeler H. (1999)
The nursing management of the does limiting toxicities experienced by patients receiving thalidomide. Proc. Clin. Oncol. Soc. Aust. A45. McCowatt S., Marx G., Pavlakis N., Monk R., Boyle F., Levi J., Bell D. and Wheeler H. (1999)
Peripheral neuropathy induced by thalidomide treatment of advanced malignancy. Proc. Clin. Oncol. Soc. Aust. A115. Marx G., Monk R., Beatson C., McCowatt S., Pavlakis N., Levi J., Bell D., Wheeler H. and Boyle F. (1999)
Not getting enough: vincirstine uptake in experimental glioma." Proc. Clin. Oncol. Soc. Australia. Boyle FM., Eller S.and Grossman S. (1999)
A systematic review of high-dose chemotherapy as a treatment strategy for breast cancer. Proc Clin. Oncol. Soc. of Australia. Boyle FM., Talbot M., Gattelari M. and Basser R. (1999)
A phase II study of thalidomide as an anti-angiogenic agent in relapsed GBM. MOGA. Marx GM., Wheeler H., Boyle FM., Levi JA. and Bell DR. (1999)
Inhibition of adenocarcinoma growth in rats by the heparanase inhibitor PI-88. Proc. Aust. Soc. Med. Res. 38:P2-5. Pavlakis N., Parish C., Freeman C., Davey R. and Wheeler H. (1999)
Drug and radiation resistance in radiation treated human lung cancer cell lines. Proc. Aust. Soc. Med. Res. 38:P2-29. Sun H P., Harvie R., Henness S., Peters G., Davey M. and Davey R. (1999)
Role of paclitaxel in the treatment of drug resistant lung cancer. Proc. Aust. Soc. Med. Res. 38:O11-2. Locke V. Davey R. and Davey M. (1999)
Regulation of the ABC transporter MRP1 in response to chemotherapy & radiotherapy. Proc. Aust. Soc. Med. Res. 38:P2-3. Henness S., O’Neill G. and Davey R. (1999)
The effect of antimitotic agents paclitaxel and vinorelbine on cell cycle and drug resistance. Aust. Flow Cytometry Group 22:10. Locke V. Davey R. and Davey M. (1999)
Detection and reversal of low level multidrug resistance in human leukaemia cells. Aust. Flow Cytometry Group 22:9. Cullen K., Davey R. and Davey M. (1999)
A review of the treatment of advanced cancer with vinorelbine at RNSH. MOGA. Marx G., Levi J., Bell D., Wheeler H. and Boyle F. (1998)
Prevention of experimental vinorelbine neuropathy with glutamate. Proc. Clin. Oncol. Soc. Aust. Boyle F., Monk R. and Wheeler H. (1998)
How safe are phyto-oestrogens in breast cancer- preliminary evidence from two rat breast cancer models. MOGA ASM. Baron-Hay S., Monk R., Thurn M., Boyle FM. (1998)
How safe are phyto-estrogens in breast cancer? Preliminary evidence from two "premenopausal" rat breast cancer models. Aust. Soc. Exp. Pathol. Boyle F., Baron-Hay S., Monk R. and Mander E. (1998)
Isoflavone modulation of multidrug resistance. Proc. Aust. Soc. Exp. Pathol. Davey M., Grech K., Fizae A. and Davey R. (1998)
Microdissection of amplified drug-resistance genes: an approach to understanding drug resistance in cancer. Aust Soc Human Genet. Peters G., Mahjoubi F., O’Neill G., MacKenzie H., Daniel A, Hill R and Davey R. (1998)
Ubiquitous expression of the ABC transporter, ARA. Proc. Aust. Soc. Med. Res. 36:P69. Henness S., O’Neill GM. and Davey RA. (1997)
Life threatening pulmonary toxicity with gemcitabine. Proc. Clin. Oncol. Soc. Aust. Pavlakis N., Bell DR., Millward M. and Levi JA. (1996)
Induction of MRP and c-myc in the H82 human small cell lung cancer cell line in response to epirubicin, cis-platinum and chlorambucil. Proc. Aust. Soc. Med. Res. 35:P2-7. Su GM., Davey MW., Davey RA. (1996)
Radiation and drug resistance mechanisms in a human t-cell leukaemia cell line. Proc. Aust. Soc. Med. Res. 35:P2-14. Harvie RM., Davey RA., Davey MW. (1996)
ara and mrp expression in a series of drug resistant sub-lines. Proc. Aust. Soc. Med. Res. 35: O4-4. Harvie RM., O’Neill GM., Henness S. and Davey RA. (1996)
Detection of multidrug resistance in human leukaemia cells. Proc. Aust. Soc. Med. Res. 35:P2-15. Davey MW., Davey RA. (1996)
Extended multidrug resistance in small cell lung cancer (SCLC). Proc. Aust. Soc. Med. Res. 34:O10. Su GM., Davey MW. and Davey RA. (1995)
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxyamide (DACA), idarubicin and paclitaxel to circumvent three multidrug resistance phenotypes in vitro. Proc. Aust. Soc. Med. Res. 34:P15 Harvie RM., Davey RA., Davey MW., Su GM., Hargrave RM. and Baguley BC., (1995)
Identification of a novel gene associated with drug resistance in a human leukaemia subline. Proc. Aust. Soc. Med. Res. 34:O11 O'Neill G., Longhurst T., Harvie RM., Wheeler H. and Davey RA. (1995)
